Adults 35 to 70, any sex, with Gulf War Illness or Chronic Fatigue. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Veterans Short Form 36-Item Health Survey Physical Component SummaryPrimary· Baseline, Weeks 4, 8, 12, 16, 20, and 24
Veterans Health Survey contains 36 items to measure health functioning from the patient's point of view. The scale is 0-100. The higher value indicates better physical health.
MFI asks questions about general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. The Multidimensional Fatigue Inventory score is 0-100. The higher value indicates more fatigue.
Change Baseline to 4 Weeks
Group
Value
95% CI
Ubiquinol
-0.6
± 8.3
Placebo
0.2
± 10
Change Baseline to 8 Weeks
Group
Value
95% CI
Ubiquinol
-1.8
± 9.9
Placebo
0.5
± 8
Change Baseline to 12 Weeks
Group
Value
95% CI
Ubiquinol
-1.4
± 10
Placebo
3.6
± 8.4
Change Baseline to 16 Weeks
Group
Value
95% CI
Ubiquinol
-3.2
± 9.5
Placebo
0.3
± 8.1
Change Baseline to 20 Weeks
Group
Value
95% CI
Ubiquinol
-0.5
± 7.5
Placebo
2.5
± 9.0
Change Baseline to 24 Weeks
Group
Value
95% CI
Ubiquinol
-2.3
± 9.7
Placebo
0.8
± 8.7
Gulf War Illness Health Symptom ChecklistSecondary· Baseline, Weeks 4, 8, 12, 16, 20, 24, and 28
The Gulf War Illness Health Symptoms Checklist asks questions about symptoms related to Gulf War Illness. The linear scale is 0-42. The higher value indicates more symptoms.
The PSQI measures quality and patterns of sleep and wake cycles and is completed by the participant. The Pittsburgh Sleep Quality Index scale is 0-21. The higher value indicates more sleep disturbance.
Change from baseline to 4 weeks
Group
Value
95% CI
Ubiquinol
-1.0
± 2.8
Placebo
0.0
± 3.1
Change from baseline to 8 weeks
Group
Value
95% CI
Ubiquinol
-1.2
± 2.9
Placebo
-0.4
± 2.8
Change from baseline to 12 weeks
Group
Value
95% CI
Ubiquinol
-1.7
± 3.4
Placebo
0.1
± 3.6
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
-1.6
± 3.0
Placebo
-1.0
± 3.0
Change from baseline to 20 weeks
Group
Value
95% CI
Ubiquinol
-0.3
± 3.7
Placebo
0.3
± 3.7
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
-1.4
± 3.5
Placebo
-0.4
± 3.5
Hamilton Anxiety Scale (HAM-A)Secondary· Baseline, Weeks 8, 16, and 24
This measure allows the participant to rate levels of anxiety. The Hamilton Anxiety Scale is 0-56. The higher value indicates more anxiety.
Change from baseline to 8 weeks
Group
Value
95% CI
Ubiquinol
-0.9
± 9.3
Placebo
1.7
± 10.3
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
-0.7
± 8.3
Placebo
-1.7
± 8.3
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
-1.5
± 9.0
Placebo
0.1
± 10.3
Hamilton Depression Scale (HAM-D)Secondary· Baseline, Weeks 8, 16, and 24
This measure allows the participant to rate level of depression. The Hamilton Depression Scale is a linear scale 0-62. The higher value indicates more depression.
Change from baseline to 8 weeks
Group
Value
95% CI
Ubiquinol
-2.4
± 6.1
Placebo
-1.3
± 4.9
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
-2.8
± 5.8
Placebo
-3.6
± 4.5
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
-2.5
± 7.0
Placebo
-2.8
± 5.8
Veterans Short Form 36-Item Health Survey: Mental Component Score (MCS)Secondary· Baseline, Weeks 4, 8, 12, 16, 20, and 24
Veterans Health Survey contains 36 items to measure health functioning from the patient's point of view. The Veterans Short Form 36-item Health Survey Mental Component Score scale is 0-100. The higher value indicates more favorable mental health.
Change from baseline to 4 weeks
Group
Value
95% CI
Ubiquinol
4.5
± 12.6
Placebo
0.4
± 12.8
Change from baseline to 8 weeks
Group
Value
95% CI
Ubiquinol
4.2
± 14.9
Placebo
3.6
± 14.8
Change from baseline to 12 weeks
Group
Value
95% CI
Ubiquinol
4.0
± 19.5
Placebo
2.8
± 10.6
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
3.8
± 15.5
Placebo
4.9
± 13.9
Change from baseline to 20 weeks
Group
Value
95% CI
Ubiquinol
-3.7
± 17.4
Placebo
3.1
± 15.8
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
2.6
± 16.3
Placebo
1.1
± 13.5
Connors Continuous Performance Test (CPT-3): Hit Reaction TimeSecondary· Baseline, Weeks 8, 16, and 24
CPT-3 asks questions about cognitive symptoms related to attention and reaction time. The Connors Continuous Performance Test Hit Reaction Time scale is 0-No limit. The higher score indicates poorer outcomes.
Change from baseline to 8 weeks
Group
Value
95% CI
Ubiquinol
10.7
± 43.1
Placebo
-1.6
± 34.3
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
17.2
± 46.9
Placebo
-3.0
± 49
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
24.0
± 46.9
Placebo
12.8
± 45.4
Connors Continuous Performance Test (CPT-3):Omissions T-scoreSecondary· Baseline, Weeks 8, 16, and 24
CPT-3 asks questions about cognitive symptoms related to attention and reaction time. The Connors Continuous Performance Test Omissions score is 0-100. 50 indicates the population mean with a standard deviation of 10. The higher T-score indicates poorer outcomes.
Change from baseline to 8 weeks
Group
Value
95% CI
Ubiquinol
-2.0
± 7.6
Placebo
-1.2
± 5.2
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
0.2
± 9.1
Placebo
-1.6
± 8.5
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
-0.4
± 9.1
Placebo
-1.6
± 7.8
Connors Continuous Performance Test (CPT-3):Commissions T-scoreSecondary· Baseline, Weeks 8, 16, and 24
CPT-3 asks questions about cognitive symptoms related to attention and reaction time. The Connors Continuous Performance Test Commissions T-score scale is 0-100. 50 indicates the population mean with a standard deviation of 10. The higher score indicates poorer outcomes.
Change from baseline to 8 weeks
Group
Value
95% CI
Ubiquinol
-3.2
± 8.0
Placebo
-2.0
± 5.3
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
-3.2
± 8.6
Placebo
-3.0
± 6.7
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
-3.5
± 8.8
Placebo
-4.5
± 7.2
Brief Visual Memory Test (BVMT): Delayed RecallSecondary· Baseline, Weeks 8, 16, and 24
BVMT asks questions about cognitive symptoms related to visual memory. The Brief Visual Memory Test Delayed Recall scale is 0-12. The higher value indicates better performance.
Change from baseline to8 weeks
Group
Value
95% CI
Ubiquinol
0.3
± 2.3
Placebo
0.3
± 2.4
Change from baseline to 16 weeks
Group
Value
95% CI
Ubiquinol
0.3
± 2.8
Placebo
0.9
± 2.0
Change from baseline to 24 weeks
Group
Value
95% CI
Ubiquinol
0.4
± 2.7
Placebo
0.4
± 2.2
Sponsor's own description
The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (SF-36), with respect to physical functioning and symptoms. Secondary outcome measures include changes from baseline levels on GWI-associated biomarkers in peripheral blood and GWI-associated symptoms of chronic pain, fatigue, insomnia, activity level, and cognitive and mental functioning.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT05972291 — Mechanisms of Gulf War Illness
· NA
· recruiting
NCT05375812 — NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)
· recruiting
NCT05675878 — Confirmation of Diet as a Treatment for Gulf War Illness
· Phase 3
· recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care
· Phase 1
· not yet recruiting
NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran
· NA
· not yet recruiting
NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness
· NA
· not yet recruiting
NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
· NA
· not yet recruiting
NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
Last refreshed: 15 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02865460.